Elucid raises $55M Series D to advance its AI software for cardiovascular CT analysis.
Key Details
- 1Boston-based Elucid closed an oversubscribed $55 million Series D round.
- 2Funding included participation from a major, unnamed, publicly traded medtech firm.
- 3Elucid has raised over $185 million to date.
- 4Its AI software assists physicians in analyzing CT scans for signs of cardiovascular disease.
- 5The funding will support clinical platform expansion, FFR-CT development (under FDA review), and continued R&D.
- 6Elucid now has four large, publicly traded strategic investors.
Why It Matters
Significant investment underscores the continued momentum and competition in AI-driven cardiovascular imaging. The funding supports further product development and regulatory progress, potentially impacting diagnostic accuracy and patient care in radiology.
Source
Radiology Business
Related News
•Radiology Business
Epsilon Health Launches With $28M to Build 'AI-Native' Imaging Practice
Epsilon Health has exited stealth mode, raising nearly $28M to launch an 'AI-native' radiology imaging group aimed at addressing the U.S. radiologist shortage.
•Radiology Business
Healthcare Leader Warns AI Will Dominate Diagnostic Radiology
A leading oncologist urges future radiologists to specialize in interventional procedures due to AI advances in image interpretation.
•Radiology Business
Harrison.ai Restructures and Launches U.S. AI-Enabled Teleradiology Venture
Harrison.ai lays off staff amid major restructuring and launches Frontier Radiology, an AI-powered U.S. teleradiology business.